88 related articles for article (PubMed ID: 19854270)
1. Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma.
Khier S; Deleuze-Masquéfa C; Moarbess G; Gattacceca F; Margout D; Solassol I; Cooper JF; Pinguet F; Bonnet PA; Bressolle FM
Eur J Pharm Sci; 2010 Jan; 39(1-3):23-9. PubMed ID: 19854270
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives.
Moarbess G; Deleuze-Masquefa C; Bonnard V; Gayraud-Paniagua S; Vidal JR; Bressolle F; Pinguet F; Bonnet PA
Bioorg Med Chem; 2008 Jul; 16(13):6601-10. PubMed ID: 18513976
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and pharmacokinetics of EAPB0203 and EAPB0503, two imidazoquinoxaline compounds previously shown to have antitumoral activity on melanoma and T-lymphomas.
Khier S; Gattacceca F; El Messaoudi S; Lafaille F; Deleuze-Masquéfa C; Bompart J; Cooper JF; Solassol I; Pinguet F; Bonnet PA; Bressolle FM
Drug Metab Dispos; 2010 Oct; 38(10):1836-47. PubMed ID: 20660102
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of imidazo[1,2-a]quinoxaline derivatives in human and rat plasma using LC/ESI-MS.
Khier S; Moarbess G; Deleuze-Masquefa C; Solassol I; Margout D; Pinguet F; Bonnet PA; Bressolle FM
J Sep Sci; 2009 May; 32(9):1363-73. PubMed ID: 19399864
[TBL] [Abstract][Full Text] [Related]
5. EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma.
Moarbess G; El-Hajj H; Kfoury Y; El-Sabban ME; Lepelletier Y; Hermine O; Deleuze-Masquéfa C; Bonnet PA; Bazarbachi A
Blood; 2008 Apr; 111(7):3770-7. PubMed ID: 18218850
[TBL] [Abstract][Full Text] [Related]
6. Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity.
Courbet A; Bec N; Constant C; Larroque C; Pugniere M; El Messaoudi S; Zghaib Z; Khier S; Deleuze-Masquefa C; Gattacceca F
PLoS One; 2017; 12(8):e0182022. PubMed ID: 28797090
[TBL] [Abstract][Full Text] [Related]
7. New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma.
Deleuze-Masquefa C; Moarbess G; Khier S; David N; Gayraud-Paniagua S; Bressolle F; Pinguet F; Bonnet PA
Eur J Med Chem; 2009 Sep; 44(9):3406-11. PubMed ID: 19278757
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of Fotemustine analogues on human melanoma cell lines.
Winum JY; Bouissière JL; Passagne I; Evrard A; Montero V; Cuq P; Montero JL
Eur J Med Chem; 2003 Mar; 38(3):319-24. PubMed ID: 12667699
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of [1,2,4]triazolo[4,3-a]quinoxaline-1,3,4-oxadiazole derivatives as potent antiproliferative agents via a hybrid pharmacophore approach.
Kaneko D; Ninomiya M; Yoshikawa R; Ono Y; Sonawane AD; Tanaka K; Nishina A; Koketsu M
Bioorg Chem; 2020 Nov; 104():104293. PubMed ID: 33010622
[TBL] [Abstract][Full Text] [Related]
10. Imidazo[1,2-
Chouchou A; Patinote C; Cuq P; Bonnet PA; Deleuze-Masquéfa C
Molecules; 2018 Nov; 23(11):. PubMed ID: 30445763
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of fotemustine and busulfan against a human neuroblastoma xenograft.
Ikeda H; Tsuchida Y; Wu J; Suzuki N; Kuroiwa M; Choi SH; Morikawa A
Oncol Rep; 2000; 7(6):1265-8. PubMed ID: 11032927
[TBL] [Abstract][Full Text] [Related]
12. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A
Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937
[TBL] [Abstract][Full Text] [Related]
13. Combination effects of SC144 and cytotoxic anticancer agents.
Oshima T; Cao X; Grande F; Yamada R; Garofalo A; Louie S; Neamati N
Anticancer Drugs; 2009 Jun; 20(5):312-20. PubMed ID: 19322070
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity and DNA damaging effects of a new nitrosourea, fotemustine, diethyl- 1-(3-(2-chloroethyl)-3-nitrosoureido) ethylphosphonate-S10036.
Tapiero H; Yin MB; Catalin J; Paraire M; Deloffre P; Rustum Y; Bizzari JP; Tew KD
Anticancer Res; 1989; 9(6):1617-22. PubMed ID: 2627116
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression.
Passagne I; Evrard A; Winum JY; Depeille P; Cuq P; Montero JL; Cupissol D; Vian L
J Pharmacol Exp Ther; 2003 Nov; 307(2):816-23. PubMed ID: 12970393
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
Del Vecchio M; Mortarini R; Canova S; Di Guardo L; Pimpinelli N; Sertoli MR; Bedognetti D; Queirolo P; Morosini P; Perrone T; Bajetta E; Anichini A
Clin Cancer Res; 2010 Dec; 16(23):5862-72. PubMed ID: 21030496
[TBL] [Abstract][Full Text] [Related]
17. Fotemustine for the treatment of melanoma.
Quéreux G; Dréno B
Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794
[TBL] [Abstract][Full Text] [Related]
18. In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea.
Fischel JL; Formento P; Etienne MC; Gioanni J; Frenay M; Deloffre P; Bizzari JP; Milano G
Cancer Chemother Pharmacol; 1990; 25(5):337-41. PubMed ID: 2306793
[TBL] [Abstract][Full Text] [Related]
19. [1,2,4]triazolo[4,3-
Patinote C; Raevens S; Baumann A; Pellegrin E; Bonnet PA; Deleuze-Masquéfa C
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513350
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo antitumor activity of the novel derivatized polyvinyl alcohol-based polymer P10(4).
Raffaghello L; Zuccari G; Carosio R; Orienti I; Montaldo PG
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3485-93. PubMed ID: 16740774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
